Connie Kang

1.4k total citations · 1 hit paper
55 papers, 949 citations indexed

About

Connie Kang is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Connie Kang has authored 55 papers receiving a total of 949 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Pulmonary and Respiratory Medicine and 8 papers in Oncology. Recurrent topics in Connie Kang's work include Skin Protection and Aging (4 papers), melanin and skin pigmentation (4 papers) and Peripheral Neuropathies and Disorders (3 papers). Connie Kang is often cited by papers focused on Skin Protection and Aging (4 papers), melanin and skin pigmentation (4 papers) and Peripheral Neuropathies and Disorders (3 papers). Connie Kang collaborates with scholars based in New Zealand, Germany and China. Connie Kang's co-authors include Yahiya Y. Syed, Paul V. Harris, Feng Xu, Hannah A. Blair, Lesley J. Scott, Caroline Fenton, Yvette N. Lamb, Emma D. Deeks, Sohita Dhillon and Xian Zhao and has published in prestigious journals such as SHILAP Revista de lepidopterología, Drugs and Current Opinion in Chemical Biology.

In The Last Decade

Connie Kang

46 papers receiving 934 citations

Hit Papers

align trajectories

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Connie Kang New Zealand	16	337	212	200	126	115	55	949
Anutosh Ganguly United States	21	552 1.6×	227 1.1×	301 1.5×	105 0.8×	221 1.9×	42	1.3k
Leiming Xu China	17	362 1.1×	258 1.2×	193 1.0×	173 1.4×	135 1.2×	43	1.0k
Kaiwen Hu China	14	260 0.8×	137 0.6×	186 0.9×	131 1.0×	74 0.6×	78	892
Zheng Han China	16	376 1.1×	153 0.7×	206 1.0×	47 0.4×	84 0.7×	50	947
Huanrong Lan China	22	474 1.4×	174 0.8×	448 2.2×	54 0.4×	187 1.6×	62	1.1k
Peng Han China	18	1.0k 3.1×	148 0.7×	204 1.0×	150 1.2×	128 1.1×	58	1.6k
Tinghe Yu China	25	707 2.1×	725 3.4×	277 1.4×	109 0.9×	131 1.1×	81	1.8k
Bijun Zhu China	25	621 1.8×	133 0.6×	218 1.1×	101 0.8×	129 1.1×	66	1.4k
Lauriane Goldwirt France	19	259 0.8×	256 1.2×	216 1.1×	130 1.0×	63 0.5×	53	1.1k
Jing Bai China	18	332 1.0×	206 1.0×	241 1.2×	74 0.6×	66 0.6×	70	859

Countries citing papers authored by Connie Kang

Since Specialization

Citations

This map shows the geographic impact of Connie Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Connie Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Connie Kang more than expected).

Fields of papers citing papers by Connie Kang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Connie Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Connie Kang. The network helps show where Connie Kang may publish in the future.

Co-authorship network of co-authors of Connie Kang

This figure shows the co-authorship network connecting the top 25 collaborators of Connie Kang. A scholar is included among the top collaborators of Connie Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Connie Kang. Connie Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Kang, Connie, et al.. (2024). Impact of a Mock OSCE on Student Confidence in Applying the Pharmacists’ Patient Care Process. SHILAP Revista de lepidopterología. 12(2). 54–54.

2.

Kang, Connie. (2024). Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo. Drugs. 84(5). 579–586. 4 indexed citations

3.

Kang, Connie. (2024). Correction: Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo. Drugs. 84(6). 745–745.

4.

Kang, Connie. (2024). Sotatercept: First Approval. Drugs. 84(7). 857–862. 9 indexed citations

5.

Fenton, Caroline & Connie Kang. (2023). Clozapine is the approved option in treatment-resistant schizophrenia and requires careful management. Drugs & Therapy Perspectives. 39(3). 107–113. 12 indexed citations

6.

Kim, Esther & Connie Kang. (2023). The treatment of post-traumatic nightmares requires more attention. Drugs & Therapy Perspectives. 39(4). 125–130. 1 indexed citations

7.

Kang, Connie. (2023). Keverprazan Hydrochloride: First Approval. Drugs. 83(7). 639–643. 10 indexed citations

8.

Fenton, Caroline & Connie Kang. (2023). Consider new therapies for the treatment and prevention of Clostridioides difficile infection. Drugs & Therapy Perspectives. 39(7). 237–242. 1 indexed citations

9.

Kang, Connie. (2023). Ravulizumab: A Review in Generalised Myasthenia Gravis. Drugs. 83(8). 717–723. 6 indexed citations

10.

Kang, Connie. (2023). Olutasidenib: First Approval. Drugs. 83(4). 341–346. 8 indexed citations

11.

Kang, Connie. (2023). Avacincaptad Pegol: First Approval. Drugs. 83(15). 1447–1453. 61 indexed citations

12.

Kang, Connie. (2022). Mosunetuzumab: First Approval. Drugs. 82(11). 1229–1234. 56 indexed citations

13.

Kang, Connie & Hannah A. Blair. (2021). Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis. Drugs. 82(1). 55–62. 48 indexed citations

14.

Kang, Connie & Matt Shirley. (2021). Amisulpride: A Review in Post-Operative Nausea and Vomiting. Drugs. 81(3). 367–375. 4 indexed citations

15.

Kang, Connie & Hannah A. Blair. (2021). Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis. Drugs. 82(1). 63–63. 1 indexed citations

16.

Kang, Connie & Yahiya Y. Syed. (2020). Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer. Drugs. 80(6). 601–607. 52 indexed citations

17.

Kang, Connie & Hannah A. Blair. (2020). Gilteritinib: A Review in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukaemia. Targeted Oncology. 15(5). 681–689. 7 indexed citations

18.

Kang, Connie & Lesley J. Scott. (2020). Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy. Molecular Diagnosis & Therapy. 24(4). 487–495. 22 indexed citations

19.

Kang, Connie, Sohita Dhillon, & Emma D. Deeks. (2019). Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer. Drugs. 79(14). 1583–1590. 20 indexed citations

20.

Kang, Connie, Sohita Dhillon, & Emma D. Deeks. (2019). Correction to: Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer. Drugs. 79(15). 1727–1727. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact